Study of TRX-920 for advanced solid tumors
Part of Cancer clinical trials.
This trial tests a new drug called TRX-920 for people with advanced solid tumors that have not responded to standard treatments or for which no standard treatment exists. The goal is to see if TRX-920 is safe and effective.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have an advanced solid tumor that has not responded to standard therapy or has no standard therapy available.
- You must be 18 years or older.
- You must have a good performance status (able to care for yourself and be up and about more than half the day).
- You must have adequate organ function (bone marrow, liver, kidneys).
- You must not have certain genetic variations in the UGT1A1 gene.
- You must not have serious heart, lung, or other medical conditions that could make the trial unsafe.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests an experimental drug (TGRX-1942) for people with advanced solid tumors or blood cancers that have stopped responding to standard treatments. The main goal is to find a safe dose and see how well the drug works.
This Phase 1/2 trial tests XTX301, a study treatment, in people with advanced solid tumors (cancers) that have already been treated and are not controlled by standard options. It may help if your cancer matches one of the study groups and you meet safety and test-tissue requirements.
This trial tests a new drug called ERX-315 for people with advanced solid tumors (like breast, ovarian, pancreatic, endometrial, or liver cancer) that have not responded to standard treatments. The goal is to see if the drug is safe and how well it works.
This trial tests a new drug called STX-001, which is injected directly into a tumor to help the immune system fight cancer. It is being studied alone or with another immunotherapy (pembrolizumab) for people with advanced solid tumors, including melanoma or triple-negative breast cancer.
This trial tests a new drug called PTX-912 for people with advanced or metastatic solid tumors that have not responded to standard treatments. It is a first-in-human study, meaning this is the first time PTX-912 is being given to people, to see how safe it is and how well it works.
This trial tests a new oral drug called SIGX1094R for people with advanced solid tumors that have not responded to other treatments. The study will check if the drug is safe and how well it works, and it requires a tumor tissue sample to look for a specific marker.
Hear when a new Advanced Solid Tumor trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.